Role of cannabinoids in the treatment of pain and (painful) spasticity

Drugs

Volumn 70, Issue 18, 2010, Pages 2409-2438

  Karst, Matthias ^a   Wippermann, Sonja ^a   Ahrens, Jrg ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

AM 1241; AM 251; Cannabinoids; CP 55940; Dronabinol; HU 308; JWH 133; Muscle spasticity; Pain; Research and development; Rimonabant; WIN 552122

Indexed keywords

ACYLGLYCEROL LIPASE; AJULEMIC ACID; CANNABINOID; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 2 RECEPTOR AGONIST; CANNABIS; CODEINE; DIAZEPAM; DIHYDROCODEINE; FATTY ACID AMIDASE; FLURBIPROFEN; INDOMETACIN; KETOPROFEN; LEVONANTRADOL; METHANEARSONATE DISODIUM; MORPHINE; NABILONE; PLACEBO; TETRAHYDROCANNABINOL;

ADAPTATION; ANTINOCICEPTION; ANXIETY; BLINDNESS; CANNABIS SMOKING; CHRONIC DISEASE; CHRONIC PAIN; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; CONTRAST; DIZZINESS; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; EUPHORIA; FATIGUE; FUTUROLOGY; HABITUATION; HALLUCINATION; HEART RATE; HUMAN; LIMB WEAKNESS; META ANALYSIS; NAUSEA; NAUSEA AND VOMITING; NERVOUSNESS; NONHUMAN; PAIN; PRURITUS; PSYCHOSOMATIC DISORDER; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SPASTICITY; SPINAL CORD; STATISTICAL SIGNIFICANCE; STRESS; SYSTEMATIC REVIEW; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING; XEROSTOMIA;

ACUTE DISEASE; ANALGESICS; ANIMALS; CANNABINOIDS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; HUMANS; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; NEURALGIA; PAIN;

ANIMALIA;

EID: 78649942879     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11585260-000000000-00000     Document Type: Review

References (167)

1. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
2. Munro S, Thomas KL, Abu-Shaar M. Molecular char- acterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
3. Jhaveri MD, Sagar DR, Elmes SJR, et al. Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol Neurobiol 2007; 36: 26-35.
4. Devane WA, Hanus L, Breuer R, et al. Isolation and structure of a brain constituent that binds to the canna-binoid receptor. Science 1992; 2581: 946-9.
5. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
6. Jonsson K-O, Holt S, Fowler CJ. The endocannabinoid system: current pharmacological research and therapeutic possibilities. Basic Clin Pharmacol Toxicol 2006; 98: 124-34.
7. Hohmann AG, Suplita II RL. Endocannabinoid mechan- isms of pain modulation. AAPS J 2006; 8: 693-708.
8. DiMarzo V, De Petrocellis L. Plant, synthetic, and en- dogenous cannabinoids in medicine. Annu Rev Med 2006; 57: 553-74.
9. Maejima T, Ohno-shosaku T, Kano M. Endogenous canna- binoid as a retrograde messenger from postsynaptic neurons to presynaptic terminals. Neurosci Res 2001; 40: 205-10.
10. Staton PC, Hatcher JP, Walker DJ, et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008; 139 (1): 225-36.
11. Schneider U, Seifert J, Karst M, et al. Das endogene Can- nabinoidsystem. Nervenarzt 2005; 76: 1062-76.
12. Russo EB, Burnett A, Hall B, et al. Agonistic properties of cannabidiol at 5-HT-1A receptors. Neurochem Res 2005; 30 (8): 1037-43.
13. Sun Y, Bennett A. Cannabinoids: a new group of agonists of PPARs. PPAR Res 2007; 2007: 23513.
14. Burstein S. PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci 2005; 77 (14): 1674-84.
15. Cravatt BF, Demarest K, Patricelli MH, et al. Super- sensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98: 9371-6.
16. Jhaveri MD, Richardson D, Chapman V. Endocannabi- noid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 2007; 152: 624-32.
17. Fowler CJ. The pharmacology of the cannabinoid system: a question of efficacy and selectivity. Mol Neurobiol 2007; 36: 15-25.
18. Fowler CJ, Holt S, Tiger G. Acidic non-steroidal antiin- flammatory drugs inhibit rat brain fatty acid amide hy-drolase in a ph-dependent manner. J Enzym Inhib Med Chem 2003; 18: 55-8.
19. Agarwal N, Pacher P,Tegeder I, etal. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007; 10: 870-9.
20. Wotherspoon GA, Fox P, McIntyre S, et al. Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 2005; 35: 235-45.
21. Romero-Sandoval A, Eisenach JC. Spinal cannabinoid re- ceptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology 2007; 106: 787-94.
22. Hohmann AG, Suplita RL, Bolton NM, et al. An en- docannabinoid mechanism for stress-induced analgesia. Nature 2005; 435: 1108-12.
23. Finn DP. Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological significance. Immunobiology 2010; 215 (8): 629-46.
24. Schlosburg JE, Kinsey SG, Lichtman AH. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J 2009; 11 (1): 39-44.
25. Naidu PS, Kinsey SG, Guo TL, et al. Regulation of in- flammatory pain by inhibition of fatty acid amide hydrolase. J Pharmacol Exp Ther 2010; 334 (1): 182-90.
26. Hohmann AG. Inhibitors of monoacylglycerol lipase as novel analgesics. Br J Pharmacol 2007; 150 (6): 673-5.
27. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-7.
28. Rahn EJ, Hohmann AG. Cannabinoids as pharmacother- apies for neuropathic pain: from the bench to the bedside. Neurotherapeutics 2009; 6 (4): 713-37.
29. Hosking RD, Zajicek JP. Therapeutic potential of cannabis in pain medicine. Br J Anaesth 2008; 101: 59-68.
30. Killestein J, Uitdehaag BMJ, Polman CH. Cannabinoids in multiple sclerosis. Drugs 2004; 64 (1): 1-11.
31. Product monograph Sativex® [online]. Available from URL: http://www.ukcia.org/research/SativexMonograph.pdf [Accessed 2010 Nov 20].
32. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17 (1): 1-12.
33. Dixon WE. The pharmacology of cannabis indica. BMJ 1899; 2: 1354-7.
34. Sanudo-Pena MC, Romero J, Seale GE, et al. Activational role of cannabinoids on movement. Eur J Pharmacol 2000; 391: 269-74.
35. Smith PB, Welch SP, Martin BR. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice. J Pharmacol Exp Ther 1994; 268: 1381-7.
36. 0 dimethylheptyl-delta8-THC-11-oic acid (CT3) in mice. Life Sci 1998; 63: 161-8.
37. Smith FL, Fujimori K, Lowe J, et al. Characterization of delta9-tetrahydrocannabinol and anandamide antinocicep-tion in nonarthritic and arthritic rats. Pharmacol Biochem Behav 1998; 60: 183-91.
38. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-80.
39. Ibrahim MM, Rude ML, Stagg NJ, et al. CB2 cannabinoid receptor mediation of antinociception. Pain 2006; 122: 36-42.
40. Costa B, Colleoni M, Conti S, et al. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 294-9.
41. Conti S, Costa B, Colleoni M, et al. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 2002; 135: 181-7.
42. Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 2003; 119: 747-57.
43. Quartilho A, Mata HP, Ibrahim MM, et al. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 2003; 99: 955-60.
44. Gutierrez T, Farthing JN, Zvonok AM, et al. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 2007; 150: 153-63.
45. Honore P, Buritova J, Besson JM. Aspirin and acetamin- ophen reduced both Fos expression in rat lumbar spinal cord and inflammatory signs produced by carrageenin inflammation. Pain 1995; 63: 365-75.
46. Nackley AG, Zvonok AM, Makriyannis A, et al. Activa- tion of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neuro-physiol 2004; 92: 3562-74.
47. Richardson JD, Kilo S, Hargreaves KM. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 1998; 75: 111-9.
48. Sokal DM, Elmes SJ, Kendall DA, et al. Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. Neuropharmacology 2003; 45: 404-11.
49. Elmes SJ, Jhaveri MD, Smart D, et al. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 2004; 20: 2311-20.
50. Elmes SJ, Winyard LA, Medhurst SJ, et al. Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 2005; 118: 327-35.
51. Hohmann AG, Farthing JN, Zvonok AM, et al. Selective activation of cannabinoid CB2 receptors suppresses hy-peralgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther 2004; 308: 446-53.
52. Succar R, Mitchell VA, Vaughan CW. Actions of N- arachidonyl-glycine in a rat inflammatory pain model. Mol Pain 2007; 3: 24.
53. Whiteside GT, Gottshall SL, Boulet JM, et al. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur J Pharmacol 2005; 528: 65-72.
54. Valenzano KJ, Tafesse L, Lee G, et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005; 48: 658-72.
55. Mitchell VA, Aslan S, Safaei R, et al. Effect of the canna- binoid ajulemic acid on rat models of neuropathic and inflammatory pain. Neurosci Lett 2005; 382: 231-5.
56. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 2008; 153: 319-34.
57. Comelli F, Giagnoni G, Bettoni I, et al. Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved. Phytother Res 2008; 22: 1017-24.
58. Di Marzo V, De Petrocellis L. Endocannabinoids as reg- ulators of transient receptor potential (TRP) channels: a further opportunity to develop new endocannabinoid-based therapeutic drugs. Curr Med Chem 2010; 17 (14): 1430-49.
59. Liu C, Walker JM. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain. J Neurophysiol 2006; 96: 2984-94.
60. Hu B, Doods H, Treede RD, et al. Depression-like beha- viour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833. Pain 2009; 143: 206-12.
61. Costa B, Siniscalco D, Trovato AE, et al. AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol 2006; 148: 1022-32.
62. La Rana G, Russo R, Campolongo P, et al. Modulation of neuropathic and inflammatory pain by the endocanna-binoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J Pharmacol Exp Ther 2006; 317: 1365-71.
63. Seltzer Z, Dubner R, Shir Y. A novel behavioural model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990; 43 (2): 205-18.
64. Helyes Z, Nemeth J, Than M, et al. Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuro-peptide release in vivo and neuropathic hyperalgesia in the rat. Life Sci 2003; 73: 2345-53.
65. Guindon J, Beaulieu P. Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. Neuro-pharmacology 2006; 50: 814-23.
66. Desroches J,Guindon J, Lambert C, et al. Modulationofthe anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol 2008; 155: 913-24.
67. Fox A, Kesingland A, Gentry C, et al. The role of central and peripheral Cannabinoid1 receptors in the anti-hyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001; 92: 91-100.
68. Dyson A, Peacock M, Chen A, et al. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 2005; 116: 129-37.
69. Guindon J, Desroches J, Dani M, et al. Pre-emptive anti- nociceptive effects of a synthetic cannabinoid in a model of neuropathic pain. Eur J Pharmacol 2007; 568: 173-6.
70. Yamamoto W, Mikami T, Iwamura H. Involvement of central cannabinoid CB(2) receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. Eur J Pharmacol 2008; 583: 56-61.
71. Bridges D, Ahmad K, Rice AS. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 2001; 133: 586-94.
72. Scott DA, Wright CE, Angus JA. Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 2004; 109: 124-31.
73. Ibrahim MM, Deng H, Zvonok A, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003; 100: 10529-33.
74. Leichsenring A, Andriske M, Backer I, et al. Analgesic and antiinflammatory effects of cannabinoid receptor agonists in a rat model of neuropathic pain. Naunyn Schmiede-bergs Arch Pharmacol 2009; 379: 627-36.
75. Raft D, Gregg J, Ghia J, et al. Effects of intravenous tet- rahydrocannabinol on experimental and surgical pain. Clin Pharmacol Ther 1977; 21: 26-33.
76. Jain AK, Ryan JR, McMahon FG, et al. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol 1981; 21: 320S-6S.
77. Greenwald MK, Stitzer ML. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 2000; 59: 261-75.
78. Buggy DJ, Toogood L, Maric S, et al. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003; 106: 169-72.
79. Naef M, Curatolo M, Petersen-Felix S, et al. The analgesic effect of oral delta9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003; 105: 79-88.
80. Rukwied R, Watkinson A, McGlone F, et al. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003; 102: 283-8.
81. Seeling W, Kneer L, Buchele B, et al. Keine synergistische Wirkung der Kombination von Delta9-Tetrahydrocannabiol und Piritramid bei postoperativen Schmerzen. Anaesthesist 2005; 55: 391-400.
82. Holdcroft A, Maze M, Dore C, et al. A multicenter dose- escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006; 104: 1040-6.
83. Roberts JD, Gennings C, Shih M. Synergistic affective an- algesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 2006; 530: 54-8.
84. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anesth 2006; 53: 769-75.
85. Wallace M, Schulteis G, Atkinson JH, et al. Dose-depen- dent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiol-ogy 2007; 107: 785-96.
86. Kraft B, Frickey NA, Kaufmann RM, et al. Lack of an- algesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. An-esthesiology 2008; 109: 101-10.
87. Redmond WJ, Goffaux P, Potvin S, et al. Analgesic and antihyperalgesic effects of nabilone on experimental heat pain. Curr Med Res Opin 2008; 24 (4): 1017-24.
88. Tart CT. On being stoned: a psychological study of mar- ijuana intoxication. Palo Alto (CA): Science and Behavior Books, 1971.
89. Sulcova E, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998; 59: 347-52.
90. Perna-Andrade AJ, Kato A, Witschi R, et al. Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science, 2009, 325, 5941, 760-4.
91. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinol Lett 2004; 25 (1/2): 31-9.
92. Campbell FA, Tramer MR, Carroll D, et al. Are cannabi- noids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 1-6.
93. Walker JM, Huang SM. Cannabinoid analgesia. Pharma- col Ther 2002; 95: 127-35.
94. Grant I, Cahn BR. Cannabis and endocannabinoid mod- ulators: therapeutic promises and challenges. Clin Neu-rosci Res 2005; 5: 185-99.
95. Azad SC, Rammes G. Cannabinoids in anaesthesia and pain therapy. Curr Opin Anaesthesiol 2005; 18: 424-27.
96. Amar MB. Cannnabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006; 105: 1-25.
97. McCarberg BH, Barkin RL. The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview. Am J Ther 2007; 14 (5): 475-83.
98. Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manage 2008; 4 (1): 245-59.
99. Beaulieu P, Ware M. Reassessment of the role of cannabi- noids in the management of pain. Curr Opin Anaesthesiol 2007; 20: 473-7.
100. Noyes Jr. R, Brunk SF, Avery DH, et al. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 18 (1): 84-9.
101. Noyes Jr. R, Brunk SF, Baram DA, et al. Analgesic effect of delta9-tetrahydrocannabinol. J Clin Pharmacol 1975; 15: 139-43.
102. Jochimsen PR, Lawton RL, VerSteeg K, et al. Effect of benzopyranoperidine, a delta-9-THC congener, on pain. Clin Phamacol Ther 1978; 24: 223-7.
103. Staquet M, Gantt C, Machin D. Effect of nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 1978; 23: 397-401.
104. Holdcroft A, Smith M, Jacklin A, et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia 1997; 52: 483-8.
105. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 2004; 59: 440-52.
106. Schley M, Legler A, Skopp G, et al. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr Med Res Opin 2006; 22 (7): 1269-76.
107. Pinsger M, Schimetta W, Volc D, et al. Benefits of an add- on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain: a randomized controlled trial. Wien Klin Wochenschr 2006; 118: 327-35.
108. Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006; 45: 50-2.
109. Narang S, Gibson D, Wasan AD, et al. Efficacy of dorna- binol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 2008; 9 (3): 254-64.
110. Haroutiunian S, Rosen G, Shouval R, et al. Add-on study of tetrahydrocannabinol for chronic non-malignant pain. J Pain Pall Care Pharmacol 2008; 22 (3): 213-17.
111. Skrabek RQ, Galimova L, Ethans K, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008; 9 (2): 164-73.
112. Ware MA, Fitzcharles M-A, Joseph L, et al. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010; 110: 604-10.
113. Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multi- center, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Sympt Manage 2010; 39 (2): 167-78.
114. Petro DJ, Ellenberger C. Treatment of human spasticity with delta9-tetrahydrocannabinol. J Clin Pharmacol 1981; 21: 413S-6S.
115. Ungerleider JT, Andrysiak T, Fairbanks L. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7: 39-50.
116. Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis [letter]. Lancet 1995; 345: 579.
117. Killestein J, Hoogervorst ELJ, Reif M, et al. Safety, toler- ability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58: 1404-7.
118. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicenter randomised placebo-controlled trial. Lancet 2003; 362: 1517-26.
119. Wade DT, Robson P, House H, et al. A preliminary con- trolled study to determine whether whole plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehab 2003; 17: 21-9.
120. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004; 10: 434-41.
121. Svendsen KB, Jensen TS, Back FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? BMJ 2004; 329: 253-61.
122. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Effi- cacy, safety, and tolerability of an oral administered can-nabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10: 417-24.
123. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow-up. J Neurol Neurosurg Psychiatry 2005; 76: 1664-9.
124. Rog DJ, Nurmikko TR, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65: 812-9.
125. Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 2006; 253: 1337-41.
126. Collin C, Davies P, Mutiboko IK, et al. Randomized con- trolled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14: 290-6.
127. Conte A, Bettolo CM, Onesto E, et al. Cannabinoid- induced effects on the nociceptive system: a neurophy-siological study in patients with secondary progressive multiple sclerosis. Eur J Pain 2009; 13: 472-7.
128. Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebocontrolled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010; 32 (5): 451-59.
129. Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006; 12: 639-45.
130. Rog DJ, Nurmikko TJ, Young CA. Oromucosal D9- tetrahydro-cannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007; 29 (9): 2068-79.
131. Centonze D, Mori F, Koch G. Lack of effect of cannabis- based treatment on clinical and laboratory measures in multiple sclerosis. Neurol Sci 2009; 30: 531-4.
132. Scully C. Cannabis; adverse effects from an oromucosal spray. Br Dent J 2007; 203 (6): E12; discussion 336-7.
133. Maurer M, Henn V, Dittrich A, et al. Delta-9-tetra- hydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci 1990; 240: 1-4.
134. Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 2003; 290: 1757-62.
135. Salim K, Schneider U, Burstein S, et al. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology 2005; 48: 1164-71.
136. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief on central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain 2004; 112: 299-306.
137. Nurmikko TJ, Serpell MG, Hoggart B, et al. Sativex suc- cessfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trail. Pain 2007; 133 (1-3): 210-20.
138. Frank B, Serpell MG, Hughes J, et al. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for neuropathic pain: randomised, crossover, double blind study. BMJ 2008; 336 (7637): 167-8.
139. Abrams DI, Jay CA, Shade SB, et al. Cannabis in pain- ful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007; 68: 515-21.
140. Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain 2008; 9 (6): 506-21.
141. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology 2009; 34: 672-80.
142. Selvarajah D, Emery CJ, Gandhi R, et al. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy. Diabetes Care 2010; 33 (1): 128-30.
143. Rintala DH, Fiess RN, Tan G, et al. Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study. Am J Phys Med Rehabil 2010; 89: 840-8.
144. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ 2010; 182 (14): E694-701.
145. Attal N, Brasseur L, Guirimand D, et al. Are oral canna- binoids safe and effective in refractory neuropathic pain? Eur J Pain 2004; 8 (2): 173-7.
146. Hagenbach U, Luz S, Ghafoor N, et al. The treatment of spasticity with D9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2007; 45: 551-62.
147. Weber J, Schley M, Casutt M, et al. Tetrahydrocannabinol (delta 9-THC) treatment in chronic central neuropathic pain and fibromyalgia patients: results of a multicenter survey. Anaesthesiol Res Pract 2009; 2009: 827290.
148. Fox A, Gentry C, Patel S, et al. Comparative activity of the anti-convulsants oxcarbazepin, carbamazepin, lamo-trigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig. Pain 2003; 105: 355-62.
149. Kaufman I, Hauer D, Huge V, et al. Enhanced anandamide plasma levels in patients with complex regional pain syndrome following traumatic injury: a preliminary report. Eur Surg Res 2009; 43: 325-9.
150. Wang T, Collet J-P, Shapiro S, et al. Adverse effects of medical cannabinoids: a systematic review. CMAJ 2008; 178 (13): 1669-78.
151. Tetrault JM, Crothers K, Moore BA, et al. Effects of marijuana smoking on pulmonary function and respiratory complications. Arch Intern Med 2007; 167: 221-8.
152. Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2010; 195: 488-91.
153. Perez-Reyes M. Pharmacodynamics of certain drugs of abuse. In: Barnett G, Chang CN, editors. Pharmaco-kinetics and pharmacodynamics of psychoactive drugs. Foster City (CA): Biomedical Publishers, 1985: 287-310.
154. Loev B, Bender PE, Dowalo F, et al. Cannabinoids: structure-activity studies related to 1,2-dimethylheptyl derivatives. J Med Chem 1973; 16: 1200-6.
155. Burstein SH. Inhibitory and stimulatory effects of canna- binoids on eicosanoid synthesis. NIDA Res Monogr 1987; 79: 158-72.
156. Dziadulewicz EK, Bevan SJ, Brain CT, et al. Naphthalen- 1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem 2007; 50: 3851-6.
157. Day A. Neuropathic pain: emerging treatments. Br J An- aesth 2008; 101: 48-58.
158. Cichewicz DL. Synergistic interactions between cannabi- noid and opioid analgesics. Life Sci 2004; 74: 1317-24.
159. Yesilyurt O, Dogrul A, Gul H, et al. Topical cannabinoid enhances topical morphine antinociception. Pain 2003; 105: 303-8.
160. Martin-Sanchez E, Furukawa T, Taylor J, et al. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med 2009; 10 (8): 1353-68.
161. Farrar JT, Young Jr JP, LaMoreaux L, et al. Clinical im- portance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94 (2): 149-58.
162. European Medicines Agency (EMEA). Doc. ref. CPMP/ EWP/252/03 rev. 1 [online]. Available from URL: http:// www.emea.europa.eu [Accessed 2010 Nov 20].
163. Watson CPN, Moulin D, Watt-Watson J, et al. Controlled- release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105: 71-8.
164. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006 Jul 19; 3: CD006146.
165. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain. Clin J Pain 2008; 24 (6): 469-78.
166. Karst M, Wippermann S. Cannabinoids against pain. Effi- cacy and strategies to reduce psychoactivity: a clinical perspective. Expert Opin Investig Drugs 2009; 18 (2): 125-33.
167. Pertwee RG. Emerging strategies for exploiting cannabi- noid receptor agonists as medicines. Br J Pharmacol 2009; 156: 397-411